Expertise in
77
conditions

Dr. Paul B. Lamb

Gastroenterology
Gut PC
480 Honeysuckle Rd, 
Dothan, AL 
Accepting New Patients
Expertise in
77
conditions
Gut PC
480 Honeysuckle Rd, 
Dothan, AL 

Overview

Paul Lamb is a Gastroenterologist practicing medicine in Dothan, Alabama.

Dr. Lamb is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Lower Esophageal Ring, Benign Esophageal Stricture, Endoscopy, and Gastrectomy.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 8 clinical trials. Dr. Lamb is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in ND

Hospital Affiliations

Medical Center Enterprise
Southeast Health Medical Center
Jackson Hospital
Flowers Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Gut PC
480 Honeysuckle Rd, Dothan, AL 36305

Additional Areas of Focus

Dr. Lamb has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Unknown
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: SHR0302
Study Phase: Phase 3
View 5 Less Clinical Trials

3 Total Publications

The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
Journal: Alimentary pharmacology & therapeutics
Published: October 08, 2014
Similar Doctors
Expertise in
89
conditions
Dr. Travis J. Rutland
Gastroenterology
Expertise in
89
conditions
Dr. Travis J. Rutland
Gastroenterology
Referral may be required

Gut PC

480 Honeysuckle Rd, 
Dothan, AL 
 (0.1 miles away)
334-836-1212
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Travis Rutland is a Gastroenterologist practicing medicine in Dothan, Alabama. Dr. Rutland is highly rated in 89 conditions, according to our data. His clinical expertise encompasses Chronic Erosive Gastritis, Gastroesophageal Reflux Disease (GERD), Lower Esophageal Ring, Gastrectomy, and Gastrostomy. Dr. Rutland is currently accepting new patients.

Expertise in
77
conditions
Dr. Samuel J. Tarwater
Gastroenterology
Expertise in
77
conditions
Dr. Samuel J. Tarwater
Gastroenterology
Referral may be required

Gut PC

480 Honeysuckle Rd, 
Dothan, AL 
 (0.1 miles away)
334-836-1212
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samuel Tarwater is a Gastroenterologist practicing medicine in Dothan, Alabama. Dr. Tarwater is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Swallowing Difficulty, Painful Swallowing, Diverticular Disease, Gastrectomy, and Endoscopy. Dr. Tarwater is currently accepting new patients.

Expertise in
72
conditions
Dr. Robert P. Albares
Gastroenterology
Expertise in
72
conditions
Dr. Robert P. Albares
Gastroenterology
Referral may be required

Gut PC

480 Honeysuckle Rd, 
Dothan, AL 
 (0.1 miles away)
334-836-1212
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Robert Albares is a Gastroenterologist practicing medicine in Dothan, Alabama. Dr. Albares is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Chronic Erosive Gastritis, Painful Swallowing, Gastrectomy, and Endoscopy. Dr. Albares is currently accepting new patients.

Frequently Asked Questions about Dr. Paul B. Lamb

How do I make an appointment with Dr. Paul B. Lamb?

You can book an appointment with Dr. Paul B. Lamb by calling their office at 334-836-1212. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul B. Lamb a top-rated expert for Gastroesophageal Reflux Disease (GERD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul B. Lamb is classified as an Distinguished expert for Gastroesophageal Reflux Disease (GERD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul B. Lamb specialize in?

While Dr. Paul B. Lamb is a Gastroenterology, they have specific expertise in Gastroesophageal Reflux Disease (GERD), Lower Esophageal Ring, and Benign Esophageal Stricture. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Paul B. Lamb participate in research or clinical trials?

Yes. Dr. Paul B. Lamb has published 3 articles and abstracts on conditions like Gastroesophageal Reflux Disease (GERD). You can view a list of Dr. Paul B. Lamb's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul B. Lamb accept my insurance?

Dr. Paul B. Lamb accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 334-836-1212 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lamb's expertise for a condition
ConditionClose
    View All 22 Distinguished Conditions
    View All 55 Advanced Conditions
    View All 67 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile